Sho Ikeda

Dr. Sho Ikeda

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2014 in Blood
Verified
Journal Article
Closed access
PDF file
MIMitsugu Ito
Mitsugu Ito
KTKazuaki Teshima
Kazuaki Teshima
SISho Ikeda
Sho Ikeda
AKAkihiro Kitadate
Akihiro Kitadate
AWAtsushi Watanabe
Atsushi Watanabe
HTHiroyuki Tagawa
Hiroyuki Tagawa
Key Points: Aberrantly diminished expression of miR-150 allows advanced CTCL to invade multiple organs with upregulation of CCR6. MiR-150 inhibits IL-22-CCL20-CCR6 autocrine signaling in advanced CTCL.

14 February 2018 in Blood Advances
Verified
Journal Article
Open access
PDF file
SISho Ikeda
Sho Ikeda
AKAkihiro Kitadate
Akihiro Kitadate
FAFumito Abe
Fumito Abe
NTNaoto Takahashi
Naoto Takahashi
HTHiroyuki Tagawa
Hiroyuki Tagawa
Key Points: Under hypoxia, KDM3A, but not IRF4, leads myeloma cells to acquire an antiapoptotic phenotype. KDM3A regulates a long noncoding RNA, MALAT1, leading to upregulation of glycolytic genes under hypoxia.

13 August 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
SISho Ikeda
Sho Ikeda
FAFumito Abe
Fumito Abe
YMYuka Matsuda
Yuka Matsuda
AKAkihiro Kitadate
Akihiro Kitadate
NTNaoto Takahashi
Naoto Takahashi
HTHiroyuki Tagawa
Hiroyuki Tagawa
Multiple myeloma (MM) is an incurable hematopoietic neoplasm derived from plasma cells, and existing in the bone marrow. Recent developments in the field of myeloma onco‐biology have enabled the use of proteasome inhibitors (PIs) as key drugs for MM. PIs can increase cell sensitivity to endoplasmic reticulum stress, leading to apoptosis of myeloma cells. PI cannot kill all myeloma cells, however; one reason of this might be activation of autophagy via hypoxic stress in the bone marrow microenvironment. Hypoxia‐inducible gene(s) that regulate autophagy may be novel therapeutic target(s) for PI‐resistant myeloma cells. Here, a hypoxia‐inducible glycolytic enzyme hexokinase‐2 (HK2) was demonstrated to contribute by autophagy activation to the acquisition of an anti‐apoptotic phenotype in myeloma cells. We found that hypoxic stress led to autophagy activation accompanied by HK2 upregulation in myeloma cells. Under hypoxic conditions, HK2 knockdown inhibited glycolysis and impaired autophagy, inducing apoptosis. The cooperative effects of a PI (bortezomib) against immunodeficient mice inoculated with HK2‐knocked down myeloma cells were examined and significant tumor reduction was observed. An HK2 inhibitor, 3‐bromopyruvate (3‐BrPA), also induced apoptosis under hypoxic rather than normoxic conditions. Further examination of the cooperative effects between 3‐BrPA and bortezomib on myeloma cells revealed a significant increase in apoptotic myeloma cells. These results strongly suggested that HK2 regulates the activation of autophagy in hypoxic myeloma cells. Cooperative treatment using PI against a dominant fraction, and HK2 inhibitor against a minor fraction, adapted to the bone marrow microenvironment, may lead to deeper remission for refractory MM.

29 April 2013 in Cancer Science
Verified
Journal Article
Closed access
PDF file
HTHiroyuki Tagawa
Hiroyuki Tagawa
SISho Ikeda
Sho Ikeda
KSKenichi Sawada
Kenichi Sawada

22 March 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
YAYoshiaki Abe
Yoshiaki Abe
SISho Ikeda
Sho Ikeda
AKAkihiro Kitadate
Akihiro Kitadate
KNKentaro Narita
Kentaro Narita
HKHiroki Kobayashi
Hiroki Kobayashi
KMKosei Matsue
Kosei Matsue

7 December 2015 in Oncogene
Verified
Journal Article
Closed access
PDF file
AKA Kitadate
A Kitadate
SISho Ikeda
Sho Ikeda
KTK Teshima
K Teshima
MIM Ito
M Ito
ITI Toyota
I Toyota
HTH Tagawa
H Tagawa